Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR …
T Payen, J Trédaniel, L Moreau, S Larivé… - … Medicine and Research, 2021 - Elsevier
Background Phase III clinical trials have demonstrated the merits of epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …
receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung …
Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib
8105 Background: The majority of NSCLC patients (pts) with activating epidermal growth
factor receptor (EGFR) mutations respond to gefitinib, however acquired resistance to this …
factor receptor (EGFR) mutations respond to gefitinib, however acquired resistance to this …
A Phase II study to evaluate the efficacy of erlotinib in advanced NSCLC patients who have wild-type EGFR and EGFR gene amplification.
T Sone, T Araya, Y Tambo, K Shibata, S Nishikawa… - 2015 - ascopubs.org
e19028 Background: Erlotinib is one of the standard therapies for previously treated patients
(pts) of advanced non-small-cell lung cancer (NSCLC) without EGFR mutations. However …
(pts) of advanced non-small-cell lung cancer (NSCLC) without EGFR mutations. However …
A phase II study of erlotinib treatment in advanced non-small cell lung cancer after failure of gefitinib: Is a clinical benefit still achievable?
B Cho, C Im, H Choi, S Shin, J Sohn, J Kim… - Journal of Clinical …, 2007 - ascopubs.org
7609 Background: To evaluate the efficacy and toxicity of erlotinib in patients (pts) with
advanced NSCLC who had progression after treatment with gefitinib. Methods: The study …
advanced NSCLC who had progression after treatment with gefitinib. Methods: The study …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
Gefitinib versus erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Y Xie, J Liang, N Su - Nan Fang yi ke da xue xue bao= Journal of …, 2015 - europepmc.org
Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of
patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with …
patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with …
Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) …
8023 Background: The purpose of the study was to evaluate the efficacy of erlotinib and the
feasibility of screening for EGFR mutations in advanced NSCLC p (chemonaive or relapsed …
feasibility of screening for EGFR mutations in advanced NSCLC p (chemonaive or relapsed …
Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors
Background Erlotinib has been approved for the management of NSCLC patients after
failure of the first or subsequent line of chemotherapy. Although the efficacy of erlotinib is …
failure of the first or subsequent line of chemotherapy. Although the efficacy of erlotinib is …
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.
N Furuya, T Fukuhara, H Saito, K Watanabe… - 2018 - ascopubs.org
9006 Background: Development of treatment for EGFR-mutated non-small-cell lung cancer
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. Combinations …
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. Combinations …
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
GR Oxnard, VA Miller - Oncology, 2010 - search.proquest.com
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …